SCHEMBL26259504

SCHEMBL26259504

COc1ccc2c(-c3ccncc3)c(OC)cc(-c3ccncc3)c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK13 O15264 5/20 0.46
▸ MAPK12 P53778 5/20 0.46
▸ MAPK11 Q15759 5/20 0.46
▸ MAPK14 Q16539 5/20 0.46
▸ NPC1 O15118 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ CYP11B1 P15538 3/20 0.43
▸ CYP11B2 P19099 3/20 0.43
▸ PDGFRB P09619 3/20 0.42
▸ PDGFRA P16234 3/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ CASP1 P29466 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26259484 0.85 KDM4E (0.51) NPC1RAB9AKDM4EMEN1ALDH1A1
SCHEMBL26259454 0.84 SQOR (0.43) MAPK14NPC1RAB9ACYP11B1CYP11B2
SCHEMBL26260037 0.81 CYP11B1 (0.53) CYP11B1CYP11B2KDM4EMEN1ALDH1A1
SCHEMBL26260061 0.81 KDM4E (0.57) NPC1RAB9ACYP11B1CYP11B2KDM4E
SCHEMBL26260045 0.78 MAOB (0.46) NPC1RAB9APDGFRBPDGFRACYP1A2
SCHEMBL26259332 0.78 PDGFRB (0.48) MAPK13MAPK12MAPK11MAPK14NPC1
SCHEMBL26259638 0.77 HIF1A (0.46) MAPK13MAPK12MAPK11MAPK14NPC1
SCHEMBL4133106 0.76 NPC1 (0.64) NPC1RAB9ACYP11B1CYP11B2PDGFRB
SCHEMBL30505317 0.76 CYP1A2 (0.55) MAPK13MAPK12MAPK11MAPK14NPC1
SCHEMBL26260002 0.74 F2 (0.44) NPC1RAB9AKDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230287262-A1 PHOTON UPCONVERSION COMPOSITION, FILM, METHOD FOR CONVERTING VISIBLE LIGHT INTO ULTRAVIOLET LIGHT, AND COMPOUND KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2023-09-14 — — US disclosed
US-20230287262-A1 PHOTON UPCONVERSION COMPOSITION, FILM, METHOD FOR CONVERTING VISIBLE LIGHT INTO ULTRAVIOLET LIGHT, AND COMPOUND KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2023-09-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230287262-A1 PHOTON UPCONVERSION COMPOSITION, FILM, METHOD FOR CONVERTING VISIBLE LIGHT INTO ULTRAVIOLET LIGHT, AND COMPOUND NUDC, CCNL2, SPIN3 MAPK13 3829/4885MAPK12 4242/4885MAPK11 4131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback